Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
See How To Can Benefit From New Copper Discoveries

IKT Insider Trading (Inhibikase Therapeutics)

Insider Ownership Percentage: 55.80%
Insider Buying (Last 12 Months): $46,470.33
Insider Selling (Last 12 Months): $0.00

Inhibikase Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Inhibikase Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inhibikase Therapeutics Share Price & Price History

Current Price: $0.67
Price Change: Price Decrease of -0.04 (-5.63%)
As of 05/18/2022 05:00 PM ET

This chart shows the closing price history over time for IKT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Last Great Value Stock
Last year it was more profitable than Disney, Square or even Tesla.

But it's just under $2 per share.

This company's unusual business model has created a rare situation where it is both cheap and highly profitable, but it may not be $2 for long.

Check out the free presentation by clicking here.
>>>

Inhibikase Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2021Milton H. WernerCEOBuy23,589$1.97$46,470.33View SEC Filing Icon  
See Full Table
The Last Great Value Stock
Last year it was more profitable than Disney, Square or even Tesla.

But it's just under $2 per share.

This company's unusual business model has created a rare situation where it is both cheap and highly profitable, but it may not be $2 for long.

Check out the free presentation by clicking here.
>>>

SEC Filings (Institutional Ownership Changes) for Inhibikase Therapeutics (NYSE:IKT)

24.49% of Inhibikase Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IKT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Inhibikase Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/13/2022Vanguard Group Inc.530,098$0.79M0.0%+10.7%2.101%Search for SEC Filing on Google Icon
5/6/2022Retirement Planning Co of New England Inc.116,402$0.17M0.1%-21.0%0.461%Search for SEC Filing on Google Icon
5/5/2022Lynwood Capital Management Inc.120,000$0.18M0.2%-52.9%0.476%Search for SEC Filing on Google Icon
5/4/2022Hamilton Lane Advisors LLC165,635$0.25M0.1%N/A0.657%Search for SEC Filing on Google Icon
5/3/2022Redmond Asset Management LLC122,682$0.18M0.1%N/A0.486%Search for SEC Filing on Google Icon
2/14/2022Murchinson Ltd.220,947$0.33M0.0%-31.2%0.878%Search for SEC Filing on Google Icon
2/14/2022State Street Corp56,900$84K0.0%N/A0.226%Search for SEC Filing on Google Icon
2/11/2022Geode Capital Management LLC79,128$0.12M0.0%+206.3%0.314%Search for SEC Filing on Google Icon
2/11/2022Renaissance Technologies LLC201,200$0.30M0.0%N/A0.799%Search for SEC Filing on Google Icon
2/8/2022Retirement Planning Co of New England Inc.147,331$0.22M0.1%N/A0.586%Search for SEC Filing on Google Icon
2/8/2022Northern Trust Corp28,872$42K0.0%+83.7%0.115%Search for SEC Filing on Google Icon
2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279%Search for SEC Filing on Google Icon
11/18/2021Bank of New York Mellon Corp39,580$75K0.0%N/A0.157%Search for SEC Filing on Google Icon
11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019%Search for SEC Filing on Google Icon
11/16/2021Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103%Search for SEC Filing on Google Icon
11/16/2021Millennium Management LLC101,278$0.19M0.0%N/A0.403%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC25,833$49K0.0%N/A0.103%Search for SEC Filing on Google Icon
11/10/2021Goldman Sachs Group Inc.27,895$53K0.0%N/A0.111%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202%Search for SEC Filing on Google Icon
8/17/2021Zeke Capital Advisors LLC93,800$0.26M0.0%+398.9%0.926%Search for SEC Filing on Google Icon
8/16/2021Antara Capital LP250,000$0.70M0.0%N/A2.467%Search for SEC Filing on Google Icon
8/16/2021Warberg Asset Management LLC90,000$0.25M0.0%N/A0.888%Search for SEC Filing on Google Icon
8/16/2021Sabby Management LLC421,200$1.18M0.2%N/A4.157%Search for SEC Filing on Google Icon
8/13/2021Altium Capital Management LP109,749$0.31M0.1%N/A1.083%Search for SEC Filing on Google Icon
8/13/2021Murchinson Ltd.320,947$0.90M0.3%N/A3.167%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.470,615$1.32M0.0%N/A4.644%Search for SEC Filing on Google Icon
8/13/2021FMR LLC433,300$1.21M0.0%+333.3%4.276%Search for SEC Filing on Google Icon
8/12/2021Kepos Capital LP700,000$1.96M0.1%N/A6.908%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC17,857$0.11M0.0%N/A0.178%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC11,224$67K0.0%N/A0.112%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC17,857$0.11M0.0%N/A0.178%Search for SEC Filing on Google Icon
5/17/2021HRT Financial LP11,614$69K0.0%N/A0.115%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Inhibikase Therapeutics logo
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Read More on Inhibikase Therapeutics

Today's Range

Now: $0.67
Low: $0.65
High: $0.73

50 Day Range

MA: $1.19
Low: $0.67
High: $1.48

52 Week Range

Now: $0.67
Low: $0.65
High: $6.41

Volume

119,004 shs

Average Volume

117,600 shs

Market Capitalization

$16.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Who are the company insiders with the largest holdings of Inhibikase Therapeutics?

Inhibikase Therapeutics' top insider investors include:
  1. Milton H Werner (CEO)
Learn More about top insider investors at Inhibikase Therapeutics.

Who are the major institutional investors of Inhibikase Therapeutics?

Inhibikase Therapeutics' top institutional investors include:
  1. Vanguard Group Inc. — 2.10%
  2. Hamilton Lane Advisors LLC — 0.66%
  3. Redmond Asset Management LLC — 0.49%
  4. Lynwood Capital Management Inc. — 0.48%
  5. Retirement Planning Co of New England Inc. — 0.46%
Learn More about top institutional investors of Inhibikase Therapeutics stock.

Which major investors are selling Inhibikase Therapeutics stock?

In the last quarter, IKT stock was sold by these institutional investors:
  1. Lynwood Capital Management Inc.
  2. Retirement Planning Co of New England Inc.

Which major investors are buying Inhibikase Therapeutics stock?

In the last quarter, IKT stock was bought by institutional investors including:
  1. Hamilton Lane Advisors LLC
  2. Redmond Asset Management LLC
  3. Vanguard Group Inc.
Invest in Artificial Intelligence Before It Changes the World
A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive. This is the golden age of investing in artificial intelligence!
Invest in this red-hot industry at pre-IPO prices.